Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 34Ovarian Neoplasms 28Small Cell Lung Carcinoma 26Squamous Cell Carcinoma of Head and Neck 23Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 13Uterine Cervical Neoplasms 12Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Lung Diseases 5Adenocarcinoma of Lung 5Thoracic Neoplasms 4

Interventions

Etoposide 3Carboplatin 3atezolizumab 2tislelizumab 1pembrolizumab 1irinotecan sucrosofate 1apatinib 1Radiotherapy 1Platinum 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Small Cell Lung Cancer Extensive Stage × Carboplatin × Clear all
NCT07227597 2026-05-28

MK-6070-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
170 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06739928 2024-12-18

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Guangzhou Institute of Respiratory Disease

Phase 2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡